Real-Time text messages from your fitness tracker: a new way to fight diabetes?

NCT ID NCT05351359

Completed Disease control Sponsor: Charles University, Czech Republic Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether a mobile health system that sends real-time text messages—prompting users to take a walk or stand up after sitting too long—can increase physical activity in people with prediabetes or type 2 diabetes. Participants receive a Fitbit tracker and brief advice from their doctor. Half also get the text-message coaching and monthly phone calls for six months. The study measures changes in daily step count, blood sugar, and other health markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a mobile health (mHealth) system that sends real-time text messages based on data from a Fitbit wearable tracker
What this could lead to: If effective, this approach could offer a practical, low-cost way for doctors to help patients with prediabetes or type 2 diabetes increase daily activity and improve health.
What could go wrong: The trial is relatively small and relies on participants consistently using the technology. The effect on long-term health outcomes like blood sugar control remains to be seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREDIABETES TYPE 2 DIABETES

Contacts and locations

Locations

Institute of General Practice

Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.